Speakers

Expand/Collapse

Ranajoy Majumdar
Director – Analytical Development
Eli Lilly & Company

Day One

Wednesday, August 31 2022

11:45 am | Roundtable - Role of Characterization Techniques in Formulation & Analytical Development of Small Oligonucleotides

Oliver Thiel
Executive Director Process Development, Drug Substance Technologies Pivotal & Commercial Synthetics
Amgen

Day Two

Thursday, September 1 2022

9:45 am | Roundtable Discussion: Sustainable Manufacturing & Novel Green Chemistry Approach

Rob Shaffer
Founder/COO
Vrata Therapeutics

Day One

Wednesday, August 31 2022

3:30 pm | Emerging Formulation Strategies to Improve Oligonucleotide PK & Delivery to Extra-Hepatic Tissues

Day Two

Thursday, September 1 2022

4:00 pm |
4:00pm | Chair’s Closing Remarks & End of Summit

8:50 am | Chair’s Opening Remarks

Ashish Garg
Director of Engineering
Eli Lilly & Company

Day One

Wednesday, August 31 2022

2:00 pm | Selection of Isolation Process for Drug Substance for Peptides & Oligonucleotides Using a Six-Sigma Approach

Bob Duff
Senior Director, Medicine Chemistry
Switch Therapeutics

Day Two

Thursday, September 1 2022

10:15 am | Exploring Attributes & Analytics

Tim Turner
Senior Manager, Synthetic Process Development
Alexion Pharmaceuticals

Day One

Wednesday, August 31 2022

4:30 pm |
4:30pm | Chair’s Closing Remarks & End of Day One
We look forward to welcoming you back for Day Two!

9:20 am | Chair’s Opening Remarks

Day Two

Thursday, September 1 2022

11:45 am | Roundtable Discussion: Reducing the Waste in Oligo Synthesis

Michael Hellerstein
VP Product Development
Vaxxinity

Day Two

Thursday, September 1 2022

1:30 pm | Successful Partnering in Tech Transfer to CROs & CDMOs

Prof Dimitrios A. Lamprou
Professor
Queens University Belfast

Day Two

Thursday, September 1 2022

11:15 am | Emerging Technologies for Biopharma Manufacturing

Zhongping Liao
Sr. Advisor
Eli Lilly & Company

Day Two

Thursday, September 1 2022

2:00 pm | Mass Spectrometry Characterization of siRNA-Antibody Conjugates

Rajendra K Pandey
Vice President, Chemistry
Cargene Therapeutics

Day Two

Thursday, September 1 2022

9:00 am | Exploring Solid Phase Synthesis of Oligos & Post-Synthesis Conjugation

Laure-Elie Carloni
Associate Director
Janssen Pharmaceuticals

Day One

Wednesday, August 31 2022

1:30 pm | It’s Not an Afterthought – The Role of Analytics in Formulation & Process Development

Nigel Richardson
Technical Director
CatSci Ltd

Gordon Lambertus
Principal Research Scientist
Eli Lilly & Company

Day Two

Thursday, September 1 2022

3:30 pm | Understanding Emerging Technology Development in Peptides

Tomas Leek
Director
AstraZeneca

Day One

Wednesday, August 31 2022

4:00 pm | Challenges in Early phase Analytics & Characterization of Synthetic Macromolecules

Naresh Badgujar
Associate Principal Scientist
AstraZeneca

Day One

Wednesday, August 31 2022

2:30 pm | Exploring the Challenges of Oligonucleotide Chemistry

Marc Lemaitre
Principal
ML Consult

Day One

Wednesday, August 31 2022

9:30 am | CMC for cGMP Manufacturing of Oligonucleotides

Mike Webb
Founder & CEO
Mike Webb Pharma

Day Two

Thursday, September 1 2022

3:00 pm | Developing Analytical Control Strategies for Therapeutic Oligonucleotides

Liping Zhou
Senior Director, Advanced Drug Delivery
AstraZeneca

Lu Tian
Director, CMC Project Management
STA Pharmaceutical

Day One

Wednesday, August 31 2022

10:00 am | Outlining Oligo Drug Delivery & LNP Platform at WuXi STA

Frank Shlafer
Process Engineer, Technology & Innovation Group
Nitto Avecia

Day Two

Thursday, September 1 2022

9:30 am | Synthesis Optimization by PAT

Kris Iyer
Chief Scientific Officer
RIGImmune Inc

Hagen Cramer
Chief Production Officer
QurAlis